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Recent studies have emphasized the important role of Stat3 activation in a number of human tumors from the viewpoint
of its oncogenic and antiapoptotic activity. In this study, we examined the role and related signaling molecules of Stat3 in
the carcinogenesis of human cutaneous squamous cell carcinoma (SCC). In 35 human cutaneous SCC samples, 86% showed
overexpression of phosphorylated (p)-Stat3, and most of those simultaneously overexpressed p-EGFR or p-Akt. Constitutive
activation of EGFR and Stat3 was observed in three SCC cell lines and four of ﬁve SCC tissues. AG1478, an inhibitor of the EGFR,
downregulated Stat3 activation in HSC-1 human SCC cells. AG1478 inhibited cell proliferation and induced apoptosis of HSC-1
cells but did not inhibit the growth of normal human epidermal keratinocytes that did not show Stat3 activation. Furthermore,
a PI3K inhibitor also suppressed Stat3 activation in HSC-1 cells to some degree. Combined treatment with the PI3K inhibitor
and AG1478 strongly suppressed Stat3 activity and dramatically induced apoptosis of HSC-1 cells. These data suggest that Stat3
activation through EGFR and/or PI3K/Akt activation plays a critical role in the proliferation and survival of human cutaneous
SCC.
1.Introduction
Stat3 activation has important implications in the cell
proliferation of cutaneous squamous cell carcinoma (SCC).
Knockdown of Stat3 activation completely prevents cell
proliferation and growth in cutaneous SCC but is not
suﬃcient to induce cell death [1]. Signaling cross talk may
be responsible for the survival mechanism of SCC [2, 3].
The epidermal growth factor receptor (EGFR) is a
member of the ErbB family, which consists of four members:
EGFR, ErbB2, ErbB3, and ErbB4. In particular, EGFR
and ErbB2 have been implicated as therapeutic targets in
various human cancers [4]. Receptor activation of the EGFR
leads to the recruitment and phosphorylation of several
downstream intracellular substrates, leading in turn to
mitogenic signaling and other tumor-promoting cellular
activities [5]. Over-expression of the EGFR in epithelial
tumors, including head and neck, lung, breast, colon, and
other solid malignant tumors, has frequently been correlated
with their poor prognosis [6–9]. In breast cancers and head
and neck SCC (HNSCC), a strong correlation between
Stat3 and EGFR expression has been observed, and it has
been suggested that the JAK/STAT pathway is one of the
important downstream routes for EGFR signaling [10].
The recruitment sites of Stat3 within the EGFR have been
identiﬁedandcharacterized,indicatingthedirectassociation
of these two molecules [11]. In addition, the existence of
EGFR independent signaling for Stat3 activation has been
reported, enhancing the importance of Stat3 activation in
tumor growth [11]. These data lead to the idea that Stat32 Journal of Skin Cancer
activation is very important for malignant proliferation of
the epithelial tumors, and that EGFR activation correlates
closely with Stat3 activation and is one of the key regulators.
Phosphotidylinositol-3 kinase (PI3K) is one of the
downstream signaling molecules of the EGFR and plays a
role in the proliferation or invasion of SCC [12, 13]. PI3K
is an important factor in the development and progression
of HNSCC [14]. There are multiple pathways that convert
PI3K to the active form. Constitutive activation of PI3K by
mutation and inactivation of its encoding gene is observed
in a signiﬁcant number of cancers [15]. Antagonists of
EGFR, PI3K, and MEK have inhibitory eﬀects on the growth
of HNSCC [16]. However, there is little information on
the role of PI3K/Akt and Stat3 pathways in mediating cell
proliferationandthecorrelationbetweenStat3andPI3K/Akt
signaling in cutaneous SCC.
In this study, we aimed to investigate the activity of
Stat3-related activators such as EGFR and PI3K/Akt in the
proliferation of a cutaneous malignant tumor, SCC, and
evaluate the therapeutic value of inhibition of the signaling
pathways.
2.MaterialsandMethods
An EGFR inhibitor (AG1478) and a phosphotidylinositol-3
kinase (PI3K) inhibitor (wortmannin) were purchased from
Calbiochem (San Diego, CA). Other reagents were from
S i g m a( S t .L o u i s ,M O ) .
2.1. Patients and Tissue Sections. Samples of SCC, including
three metastasis cases and adjacent skin, were obtained from
32 patients, 16 males and 16 females, with an average age of
74 years (range: 41–101 years). All subjects provided written
informed consent prior to enrollment in the study. Surgically
removed tissue samples were ﬁxed in 10% neutral buﬀered
formaldehyde and paraﬃn embedded for histopathology or
immediately frozen in liquid nitrogen for nuclei extracts.
2.2. Cells and Cell Culture. T h r e eh u m a nc u t a n e o u sS C C
cells lines, HSC-1, -3, and -4, were kindly provided by Dr.
Katagaka of the Yamagata University School of Medicine
[17].Theimmortalizedhumankeratinocytecellline,HaCaT,
was kindly provided by Dr. Fusenig [18]. These cells were
grown in Dulbecco’s modiﬁed Eagle’s medium (Life Tech-
nologies, Gaithersburg, MD) supplemented with 10% fetal
bovine serum, 100U/mL penicillin, and 100μg/mL strep-
tomycin. Primary human epidermal keratinocytes (HEKs)
were purchased from KURABO (Osaka, Japan). HEKs were
grown in keratinocyte serum-free medium (SFM) supple-
mented with human keratinocyte growth supplement and
PSA (penicillin, streptomycin, and amphotericin B) solution
(Gibco, Grand Island, NY). Cells were maintained in a
standard culture incubator with humidiﬁed air containing
5% CO2 at 37◦C.
2.3. Immunohistochemistry. Skin specimens of 5μmp a r -
aﬃn-embedded sections were stained immunohistochem-
ically using a streptavidin-biotin-peroxidase complex pro-
cedure provided by the DAKO CSA System, HRP (DAKO,
Carpinteria, CA), according to the manufacturer’s protocol.
In brief, the sections were incubated at room temperature
for 30 minutes with an anti-phospho-EGFR monoclonal
antibody (mAb) (Tyr1173) (53A5), an anti-phospho-Akt
(Ser473) (D9E) mAb, or a phospho-Stat3 (Tyr705) antibody
(Cell Signaling Technology, Beverly, MA). After three washes
with PBS, the samples were incubated with biotinylated
antirabbit IgG and the avidin-biotin complex at room
temperature for 15 minutes. Staining was completed by a
5-minute incubation with 3, 3’-diaminobenzidine tetrahy-
drochloride.
2.4. Electrophoretic Mobility Shift Assay (EMSA). Nuclear
extracts from surgical tissues were puriﬁed following the
method described by Corsini et al. [19], with slight mod-
iﬁcations. The tissues were frozen immediately in liquid
nitrogen, and then 8μm slices from the tissue were cut
with a cryostat. The sections were washed with PBS and
were homogenized in 1mL of a hypotonic lysis buﬀer
( 1 0m MH E P E S ,p H7 . 8 ,1 0m MK C l ,2m MM g C l 2,1m M
dithiothreitol, 0.1mM ethylenediaminetetraacetic acid, and
0.1mMphenylmethylsulfonylﬂuoride)withatissuehomog-
enizer for 20 seconds. Homogenates were kept on ice for
15 minutes, then 125μL Nonidet P-40 solution was added
and mixed for 15 seconds, and the mixture was then
centrifuged for 30 seconds at 12000rpm. Nuclear extracts
from the pellets or cells were prepared and EMSAs were
performed essentially as described earlier [20]. Binding
reaction mixtures (20μL) containing 5μg nuclear extract
protein, 2μg poly (dI-dC) (Amersham Pharmacia Biotech,
Piscataway, NJ, Sweden), 32P-labeled probe (Stat3), 50mM
NaCl, 2mM MgCl2,0 . 2 m MN a 2EDTA, 1mM DTT, 10%
(v/v) glycerol, and 4mM Tris-HCl (pH 7.9) were incubated
for 30 minutes at room temperature. Proteins were separated
by electrophoresis in native 6% polyacrylamide gels using
a Tris-borate-EDTA running buﬀer (12.5mM Tris-borate
containing 0.25mM Na2EDTA, pH 8.0), followed by autora-
diography. The Stat3 probe (Santa Cruz Biotechnology,
Santa Cruz, CA) 5 ...GAT CCT TCT GGG AAT TCC
TAG ATC...3 ;3  ...CTA GGA AGA CCC TTA AGG ATC
TAG...5  was labeled with [γ-32P] dATP (Du Pont NEN,
Boston, MA) using T4 polynucleotide kinase (Boehringer
MannheimRoche, Mannheim, Germany).
2.5. Immunoprecipitation and Immunoblot Analysis. The
cells were washed with ice-cold D-PBS containing 200μM
sodium orthovanadate (Na3VO4), frozen immediately in
liquid nitrogen, and then lysed in lysis buﬀer (25mM Tris-
HCl, pH 7.6, 200mM boric acid, 150mM NaCl, 50mM
NaF, 5 mM Na2EDTA, 1% Triton X-100, 10mM sodium
pyrophosphate, 2mM EGTA, 20mM p-nitrophenyl phos-
phate, 1% BSA, 20μMN a 3VO4, and 2mM DTT) containing
protease inhibitors (2μg/mL each of aprotinin, leupeptin,
pepstain, antipain, and 100μg/mL PMSF). The lysates were
centrifuged at 10,000 × ga t4 ◦C for 15 minutes, and the
resulting supernatants were subjected to immunoprecipi-
tation or immunoblot analysis. Protein concentrations in
the supernatants were quantitated using the Coomassie plus
protein assay reagent (Bio-Rad Loboratories, Tokyo, Japan).Journal of Skin Cancer 3
Samples (20μg protein each) for immunoblotting were
separated on 8% SDS-polyacrylamide gel electrophoresis
gels for Akt and Stat3 and were blotted onto Hybond-ECL
nitrocellulose membranes (Amersham Pharmacia Biotech,
Piscataway, NJ, USA), followed by blocking with 5% skim
milk in Tris-buﬀered saline for 2 hours at room temperature,
and were then probed with a primary antibody to phospho-
Akt (Ser473), phospho-Stat3 (Tyr705 or Ser727) antibody
(Cell Signaling Technology), or a horseradish peroxidase
(HRP)-conjugated anti-phosphotyrosine antibody, PY20
(Santa Cruz Biotechnology, Santa Cruz, CA), overnight at
4◦C. Bound antibodies were detected using the ECL Western
blotting detection reagent (Amersham Pharmacia Biotech).
After ﬁlm exposure, the membranes were washed 4 times for
5 minutes each in PBS-Tween 20 and were then incubated
for 30 minutes at 50◦C in stripping buﬀer (62.5mM Tris
HCl pH 6.8, 2% SDS, and 100mM 2-mercaptoethanol).
The membranes were blocked with 5% skim milk again,
and then reprobed with an antibody to Akt antibody or
Stat3 antibody (Cell Signaling Technology) or reblotted with
human actin (Santa Cruz) as a loading control overnight at
4◦C. Supernatants for immunoprecipitation were incubated
at 4◦C with the anti-EGFR (1005) antibody (Santa Cruz)
bound to G-Sepharose beads (2μgA bp e r2 0 μLb e a d s ;
Amersham Pharmacia Biotech) for 4 hours, after which the
beads were washed twice with 1mL WG buﬀer (50mM
HEPES-NaOH, pH 7.6, 150mM NaCl, 0.1% Triton X-100)
and resuspended in SDS sample buﬀer. Quantiﬁcation of
protein expression was done using ImageJ analysis software
(version 1.44b) (Bethesda, MD, USA).
2.6. Cell Proliferation Assay. Cell growth was determined
using the MTS cell proliferation assay (Promega, Madison,
WI). Brieﬂy, HSC-1 cells or HEK were cultured in 96 well
plates. Twenty-four hours after seeding, the cells were treated
with AG1478 (0.25 or 2.5μM) for the indicated time and
the medium and substrates were exchanged every 24 hours,
after which the MTS reagent was added and allowed to
react for 2 hours. Absorbance at 490nm was measured using
a microplate reader (Emax; Molecular Devices, Sunnyvale,
CA). Cell growth is expressed as a percentage of that in
nontreated cells at each indicated time point. DMSO was
used as a control for AG1478 treatment. To assess the eﬀect
of serum on cell growth, the cells were seeded at a density
of 1 × 104 cells/well in the medium with serum in 96
well plates. The medium was exchanged every 24 hours for
medium with or without serum. Cell growth was evaluated
at 0 hour, 36 hours, and 48 hours after the ﬁrst exchange
of medium. The results are expressed as a percent ratio of
serum-free to serum conditions for HaCaT and HSC-1 cells.
2.7. Detection of Cell Death. Apoptosis of cells was ana-
l y z e db yﬂ o wc y t o m e t r y .E a r l yi na p o p t o s i s ,m e m b r a n e
phospholipid phosphatidylserine (PS) is translocated to the
outer leaﬂet of the plasma membrane. Annexin V is a 35-
36kD Ca2+ dependent, phospholipid-binding protein that
has a high aﬃnity for PS. Staining with Annexin V-FITC
(BD Pharmingen, San Diego, CA) in conjunction with the
vital dye propidium iodide (PI) (Sigma) was performed to
identify early apoptotic cells. HSC-1 cells were treated with
control solvent or with AG1478 (0.25 or 2.5μM) for 12
hours. Cells were scraped, then spun down, and washed
twice with 5mL cold PBS. The cells were resuspended in
bindingbuﬀer(0.01MHEPES,pH7.4;0.14MNaCl;2.5mM
CaCl2) at a concentration of 1 × 106 cells/mL and then
stained according to the manufacturer’s protocol. Cells were
analyzed using a FACS caliber ﬂow cytometer (BD, San Jose,
CA). Apoptotic cells exclude all those dyes which are used
in cell viability assays, such as PI, while necrotic cells do
not. In cells with a damaged cell membrane, PI induces
a red ﬂuorescence of the DNA, while it is excluded from
cells with a preserved plasma membrane [21]. The lower left
quadrant (LL) of the cytograms shows the viable cells, which
excludePIandarenegativeforAnnexinV-FITCbinding.The
upper right quadrant (UR) represents nonviable, necrotic
cells, positive for Annexin V-FITC binding and PI uptake.
The lower right quadrant (LR) represents apoptotic cells,
Annexin V-FITC is positive but PI is negative.
2.8. Statistical Analysis. Data are expressed as mean ±
standard deviation of at least three separate experiments.
Statistical analyses were performed using Prism 5 software
(GraphPad Software, San Diego, CA). Unpaired experimen-
tal groups were compared with the Student’s t-test. Value of
P<. 05 was considered to be statistically signiﬁcant.
3. Results
3.1. EGFR, Akt, and Stat3 Are Frequently Overexpressed
in Human Cutaneous SCC Tissues. Thirty-ﬁve paraﬃn-
embedded sections of SCC including 2 metastatic lesions
wereexaminedimmunohistochemicallyfortheexpressionof
phosphorylated (p)-EGFR, p-Akt, and p-Stat3, and the cases
in which they were expressed in more than 20% of the cells
were deﬁned as positive (Figure 1, Table 1).
Twenty-ﬁve of the 35 SCCs showed positive expression
of p-EGFR in tumor cells. The reactivity of p-EGFR was
seen mainly in the cytoplasm and partially in the nucleus
(Figure 1(a)). P-Akt was expressed in the cytoplasm and
nucleusofatypicalcells(Figure 1(b)).Strongerp-Aktexpres-
sion was seen in atypical cells surrounding the invasive
lesions into the dermis. We evaluated Stat3 activation by the
expression of both phospho-Tyr705 and phospho-Ser727.
Most of the cases showed phosphorylation on both sites,
mainly in the nuclei, and partially in the cytoplasm, though
the expression at each site diﬀered in degree. Overall,
expression of Tyr705 was considered to be positive for p-
Stat3 (Figure 1(c)). Thirty of the 35 SCCs showed a positive
reaction for p-Stat3. Actinic keratosis, a premalignant lesion
of SCC, also over-expressed p-Stat3 if the adjacent SCC was
also positive for p-Stat3. None of p-EGFR, p-Akt, or p-Stat3
were seen in tissue adjacent to the tumor or normal skin
(Figures 1(d), 1(e),a n d1(f)). Twenty-seven of 30 p-Stat3
positive cases over-expressed both or either of p-EGFR and
p-Akt, and three of the 30 cases showed negative for both
p-EGFR and p-Akt expression. Eight of 35 SCCs showed
over-expression of p-EGFR and p-Stat3 without p-Akt over-
expression. In contrast, only two of the 35 cases showed4 Journal of Skin Cancer
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(a)
p-Akt
(b)
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Figure 1: Over-expression of p-EGFR, p-Akt, and p-Stat3 in human cutaneous SCC tissues. Paraﬃn-embedded serial sections of
SCC from the same patient were examined immunohistochemically for p-EGFR, p-Akt, and p-Stat3 (tyr705) expression. Characteristic
immunostaining of p-EGFR, p-Akt and p-Stat3; original magniﬁcation: ×200. P-EGFR (a) and p-Akt (b) protein were overexpressed mainly
in the cytoplasm and partially in the nucleus. P-Stat3 (tyr705) protein was detected in the nuclei (c). None of p-EGFR p-Akt or p-Stat3
protein were seen in normal skin ((d), (e), (f)); original magniﬁcation: ×100.
over-expression of p-Akt and p-Stat3 without p-EGFR over-
expression. Two of the 3 metastatic lesions over-expressed p-
Stat3 as well as p-EGFR and p-Akt (Table 1).
Next,toevaluatethefunctionalactivityofp-Stat3protein
expression in vivo, the Stat3 DNA binding activity of SCC
tumors and normal skin was investigated. Four of 5 human
SCC tissues showed strong Stat3 DNA binding activity while
no DNA binding activity was seen in normal skin samples
(Figure 2). The results of Stat3 DNA binding activity were
consistent with those of the immunohistochemical study;
thatis,allofthe4tissueswithpositiveDNAbindingactivities
werepositivelystainedforp-Stat3byimmunohistochemistry
and one case without DNA binding activity was negative for
protein expression (Table 1).
3.2. EGFR and Stat3 Are Activated in Human SCC Cell Lines
but Less in Human Epidermal Primary Keratinocytes or in
HaCaT Cells. ThestatusofEGFRandStat3phosphorylation
w a si n v e s t i g a t e di nH E K ,H a C a T ,a n dh u m a nS C Cc e l l
lines (HSC-1, -3, and -4). Cells were cultured in serum-free
medium for 24 hours before harvest, and then lysates were
utilized for immunoprecipitation or immunoblotting. HSC-
1, -3, and -4 cells showed strong expression of p-EGFR while
HEK, and HaCaT cells showed little p-EGFR expression
(Figure 3(a)). Although the medium for HEK contains EGF
(1∼2ng/mL), no detectable EGFR phosphorylation was
observed in HEK (Figure 3(a)). The DNA binding activity of
Stat3 was analyzed using EMSA. Constitutive activation of
Stat3 was observed in HaCaT, HSC-1, -3, and -4 cells under
conventional culture conditions (Figure 3(b)). HaCaT cells
showed little Stat3 DNA binding activity when they were
cultured in serum-free medium while the addition of fetal
calf serum activated Stat3 within 24 hours (Figure 3(c)). In
Stat3
Cold normal skin P M Case 6 Case 7 Case 10
Case 5
Figure 2: Analysis of Stat3 activation in human cutaneous SCC
tissues. Nuclear extracts were generated from surgical tissues. In
case5,normalskin,primarylesion(P),andmetastaticlesion(M)of
SCC from the same patient were analyzed for Stat3 activation using
EMSA with a 32P-labeled DNA probe to detect binding activity
of Stat3. Speciﬁcity of the DNA-binding complex was evaluated
by competition with excess unlabeled Stat3 oligonucleotide (cold).
Stat3 activation of the primary lesions of the other 3 cases was
also analyzed. Three of the 4 primary lesions and a metastatic
SCC showed the strong DNA binding activity of Stat3 while little
activation was seen in normal skin samples examined and in one
primary SCC lesion (case 6). Data of normal skin are representative
of 4 normal skin samples.
contrast, cultivation of HSC-1 cells in serum-free medium
reduced little amount of the Stat3 DNA binding activity
(Figure 3(c)). The basal activity of Stat3 in HEK was very low
(Figures 3(b) and 3(c)).
3.3. Inhibitor of EGFR Downregulates the Constitutive Activa-
tion of Stat3 in HSC-1 Cells, and a Combination of Inhibitors
of EGFR and PI3K/Akt Abrogates Stat3 Activation. The
correlation between Stat3 activation and EGFR activation
was examined using the EGFR-speciﬁc inhibitor tyrphostin
AG1478. Expression of p-EGFR was reduced by treatmentJournal of Skin Cancer 5
Table 1: Immunohistochemical analysis of human cutaneous SCC tissues.
Case Age Sex Site p-EGFR p-Akt p-Stat3 EMSA Stat3
16 4 M B a c k , p r i m a r y l e s i o n + − +N . D .
1  Lymph node, metastasis of case 1 + − +N . D .
28 9 F F a c e + + + N . D .
34 1 F F o o t − + − N.D.
46 5 M H e a d + + + N . D .
5 61 F Hand, primary lesion + + + +
5  Lymph node, metastasis of case 5 + + + +
6 58 M Thigh − + −−
7 81 M Foot ﬁnger + + + +
85 4 F L o w e r l e g −− − N.D.
9 41 F Hand ﬁnger + − +N . D .
10 72 M Forehead + + + +
11 81 F Face + − +N . D .
12 72 F Face + + + N.D.
13 75 M Face + + + N.D.
14 90 F Face −− − N.D.
15 62 M Face + + + N.D.
16 64 M Face + + + N.D.
17 80 F Face −−+N . D .
18 96 F Face + + + N.D.
19 88 M Head − ++ N . D .
20 81 M Lower leg + + + N.D.
21 77 M Head + + + N.D.
22 89 F Head + − +N . D .
23 71 F Face − ++ N . D .
24 93 F Vulva + + + N.D.
25 71 M Foot back + + + N.D.
26 81 M Head + − +N . D .
27 55 F Sole −−+N . D .
28 101 M Face + − +N . D .
29 87 F Forearm + − +N . D .
29  Lymph node, metastasis of case 29 + + + N.D.
30 73 M Thigh −−+N . D .
31 87 M Scrotum + − +N . D .
32 74 F Lip −− − N.D.
Positive cases/Total 25/35 20/35 30/35 4/5
+: positive, −:n e g a t i v e ,N . D . :n o td o n e .
with AG1478 (Figure 4(a)). Constitutive activation of Stat3
in HSC-1 cells was also downregulated by AG1478 in a
dose-dependent manner (Figure 4(d)). However, the DNA
binding activity of Stat3 was still observed in HSC-1 cells
after treatment with 2.5μM of AG1478, indicating that
alternative pathways are involved in Stat3 activation in
HSC-1 cells. To explore the distinct signal that activates Stat3
in SCC, Akt activation was investigated by immunoblot
analysis. Low expression of p-Akt and p-Stat3 protein was
observed in HEK and HaCaT cells in serum-free conditions
(data not shown). Over-expression of p-Akt protein as
well as p-Stat3 protein was observed in SCC cell lines.
P-Akt protein expression was slightly reduced after 24-hour
serum starvation in HSC-1 cells, but the Akt activity was
still maintained even under serum-free conditions. In
contrast, the dramatically reduced level of p-Akt expression
was observed in HaCaT cells in serum-free conditions
(Figure 4(b)). We investigated the role of PI3K/Akt signaling
on Stat3 activation in HSC-1 cells. The activation of Akt was
abrogated by treatment with a PI3K inhibitor, wortmannin,
but not by treatment with AG1478 (Figure 4(c)). The eﬀect
of treatment with wortmannin on Stat3 phosphorylation
and DNA binding activity was examined by EMSA in HSC-1
cells. Each treatment, respectively, suppressed the activity of
Stat3 to some degree, and the combination of AG1478 and
wortmannin showed an additive eﬀect on the suppression6 Journal of Skin Cancer
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Figure 3: Analysis of EGFR and Stat3 activation in human
epidermal primary keratinocytes (HEK), HaCaT cells, and human
SCC cells. Cells were incubated in serum-free medium for 24 hours,
and then cell lysates were extracted from HEK, HaCaT cells, HSC-1,
-3, or -4 cells. Total 100μg of protein in each lysate were subjected
to immunoprecipitation (IP) with the anti-EGFR antibody. The
immunoprecipitates were separated by SDS-PAGE and subjected
to immunoblot analysis with an anti-phosphotyrosine antibody,
PY20. The same membrane was then reprobed with the anti-EGFR
antibody. Data are representative of three independent experiments
(a). Nuclear extracts from HEK, HaCaT cells, HSC-1, -3, or -4 cells
under the regular condition were analyzed using EMSA with a 32P-
labeled DNA probe to detect DNA binding activity of Stat3 (b).
HSC-1 or HaCaT cells were seeded in medium with 10% fetal calf
serum, and the cells were cultured for 24 hours, after which they
were cultured in medium with or without 10% fetal calf serum for
24 hours and Stat3 activation was analyzed using EMSA (c).
of Stat3 DNA binding activity (Figure 4(d)). Next, the link
between Stat3 activation and Akt activation was examined
by immunoblotting with anti-phospho-antibody to Stat3
or Akt. After preincubation in the absence of serum for
24 hours, HSC-1 cells were incubated in the presence or
absence of 100nM insulin for 15 minutes and then lysed.
Immunoblotting with the anti-phospho-antibody of Akt
(ser 473), Stat3 (tyr705), or Stat3 (ser 727) and the total
antibody of Akt or Stat3 showed synchronized upregulation
of both proteins, and a stimulator of Akt activation, insulin,
resulted in signiﬁcant increase on phosphorylation of both
Tyr705 and Ser727 (Figure 4(e)). P-Akt appeared to be a
candidate as an activator of Stat3 in HSC-1 cells.
3.4. An EGFR Inhibitor Suppresses the Growth of HSC-1 Cells
but Not That of HEK. The eﬀects of AG1478 on the growth
of HSC-1 cells and HEK were evaluated using the MTS
assay. Cell growth is expressed as a percentage of that in
untreated cells at each indicated time point. Treatment with
AG1478 signiﬁcantly suppressed the growth of HSC-1 cells
(P<. 01 or .05) (Figure 5(a)). After 72 hours of AG1478
treatment at a concentration of 2.5μM, the cell density was
suppressed signiﬁcantly to 38% of untreated HSC-1 cells
(P<. 01) (Figure 5(a)). Alternatively, the same treatment
did not aﬀect the growth of HEK for at least 72 hours
under culture conditions containing 1 or 2ng/mL EGF
(Figure 5(b)). HaCaT cells grew slowly in the serum-free
medium. To examine the eﬀect of serum in the culture
medium on the growth of HSC-1 or HaCaT cells, they were
seeded in medium with 10% fetal calf serum, after which the
medium was exchanged for serum-free medium or medium
with 10% fetal calf serum every 24 hours. The growth of
HSC-1 and HaCaT cells was monitored using the MTS assay
and was expressed as the percent ratio (serum-free/serum)
(Figure 5(c)). The percent ratio (serum-free/serum) of cell
growth at 48 hours was 38% and 71% in HaCaT cells and
HSC-1 cells, respectively. The proliferation of HaCaT cells
under serum-free conditions was signiﬁcantly decreased
at 48 hours (P<. 05) (Figure 5(c)). These values were
signiﬁcantly diﬀerent, indicating that the proliferation of
HaCaT cells is stimulated more by serum.
3.5. An EGFR Inhibitor and a PI3K Inhibitor Induce Apoptosis
in HSC-1, 3, and 4 Cells. To elucidate the role of EGFR
activation on apoptosis, double staining for Annexin V-FITC
binding and for cellular DNA using PI was performed on
HSC-1, 3, and 4 cells. In the control, 0.54% of the cells
were apoptotic. Apoptotic cell populations were increased
by treatment with AG1478 in a dose-dependent manner.
AG1478 at doses of 0.025, 0.25, or 2.5μM increased the
apoptotic cell population (data not shown). No induction of
apoptosis by AG1478 was observed in HEK. The apoptosis
was also induced in HSC-1 cells by treatment with a PI3K
inhibitor, wortmannin (P<. 01, when compared with
untreated) (Figure 6(a)). The percentage of apoptotic
cells induced by wortmannin at 100nM was signiﬁcantly
(P<. 05) lower than that by AG1478 at 2.5μMi nH S C - 1
cell lines (Figure 6(b)). The greatest induction of apoptosis
(48.2%) (P<. 05, when compared with AG1478) among
the treatments tested in this study was obtained by the
combined treatment of AG1478 at 2.5μM and wortmannin
at 100nM in HSC-1 cells (Figure 6(b)). PI staining showed
that cell viability (UR) was not aﬀected by these treatments
(Figure 6(a)). Although a similar trend was observed in
HSC-3 and 4 cells, the diﬀerence between apoptosis rates
induced by each treatment in HSC-3 and 4 cells was not as
big as in HSC-1 cells (Figure 6(b)).Journal of Skin Cancer 7
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Figure 4: Eﬀect of wortmannin, AG1478, and insulin on activation of Stat3 and Akt in HSC-1 cells. HSC-1 cells were incubated in serum free
medium for 24h, and were then treated with AG1478 at the indicated concentration for 1h. The cell lysates were subjected to IP with the
anti-EGFR antibody. The same membrane was then reprobed with the anti-EGFR antibody (a). The cells were incubated with or without
serum for 24h, and then each lysate was immunoblotted with anti-p-Akt antibody, and then reprobed with the anti-Akt antibody (b). HSC-
1 cells were incubated in serum free medium for 24h, and were then treated with AG1478 or wortmannin for 1h. The cell lysates were
immunoblotted with the anti-p-Akt antibody, and then reprobed with the anti-Akt antibody (c). HSC-1 cells were incubated in serum free
medium for 24h, and were then treated with AG1478 and/or wortmannin at the indicated concentration for 1h. DNA binding activity of
Stat3 was analyzed using EMSA (d). HSC-1 cells were incubated without serum for 24h, and were then treated with or without insulin
for 15min. The cell lysates were immunoblotted with each of the anti-p-Akt or p-Stat3 antibody and then reblotted with human actin as a
loading control. The same membrane was reprobed with the anti-Stat3 or Akt antibody (e). The bar graphs are expressed as the relative ratio
of p-Akt or Stat3 protein expression to actin protein expression by densitometry. Data are mean ± SD of three independent experiments.
P< . 05 are statistically signiﬁcant when compared with the non-treated control (e).8 Journal of Skin Cancer
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Figure 5: Eﬀect of AG1478 on proliferation of HSC-1 cells and HEKs. After HSC-1 cells or HEKs were incubated with AG1478 (0.25 or
2.5μM) for indicated periods, cell proliferation was analyzed using the MTS assay ((a), (b)). Cell growth of HSC-1 cells (a) or HEKs (b)
was expressed as a percentage of that in untreated cells at each indicated time point up to 72 hours. HSC-1 or HaCaT cells were seeded in
medium with 10% fetal calf serum and were cultured for 24 hours. The medium was then changed to serum-free medium or medium with
10% fetal calf serum. The growth of HSC-1 and HaCaT cells was monitored using the MTS assay at 0 hour, 36 hours, and 48 hours after the
change of medium and was expressed as the percent ratio (serum-free/serum) (c). Data are mean ± SD of at least three experiments. P<. 05
when compared with each group.Journal of Skin Cancer 9
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Figure 6: Analysis of apoptosis induced by AG1478 and wortmannin in HSC-1 cells. HSC-1 cells were incubated with AG1478 and/or
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(PI) and analyzed by ﬂow cytometry (a). Data are representative of at least four independent experiments. Annexin V-FITC positive and PI
negative cells are apoptotic (lower right quadrant) (a). Annexin V-FITC positive and PI positive cells are necrosis (upper right quadrant) (a).
HSC-1, 3, and 4 cells were incubated with AG1478 (2.5μM) and/or wortmannin (100nM) for 24 hours. Cells were incubated with Annexin
V-FITC in a buﬀer containing propidium iodide (PI) and analyzed by ﬂow cytometry. Results are means ± SD of at least three independent
experiments (b). Statistical signiﬁcance of the diﬀerence between each group was determined using Student’s t-test and analysis of variance.
4. Discussion
This study demonstrated the crucial role of Stat3 in the pro-
liferation of cutaneous SCC and the important contribution
ofthedualsignalingofEGFRandPI3K/Aktontheactivation
of Stat3. In vivo analysis using immunohistochemistry and
EMSA reveals that Stat3 activation is frequently observed
in association with EGFR and/or Akt activation in human
cutaneous SCC. Nearly 86% of human cutaneous SCCs
expressed p-Stat3 as shown in Table 1. No preferential
regions for p-Stat3 expression were found in this study. In
accordance with in vivo results, we easily found three human
cutaneous SCC cell lines, which showed constitutive Stat3
activation. Although Stat3 activation was not shown in all
SCC cell lines, Stat3 appears to be activated in most cases of
cutaneous SCCs.
In agreement with studies emphasizing the critical role
of EGFR on Stat3 activation in the carcinogenesis of mouse
or human HNSCC [22, 23], we also demonstrated the
importance of EGFR activation in Stat3 activation in human
cutaneous SCC. It has been suggested that the molecular
mechanisms for EGFR activation are autocrine regulation or
geneampliﬁcationinotherorganmalignanciessuchasbreast
orbraintumors[24–26].However,theautocrinemechanism
may not be relevant in HSC-1 cells since the addition of a
neutralizing antibody to EGF did not aﬀect activation of the
EGFR in the cells (data not shown).
Ad i ﬀerent reaction to serum regarding growth and
Stat3 activation between HaCaT cells and HSC-1 cells was
observed in our study. The Stat3 activity of HaCaT cells was
markedly stimulated by serum, while that of HSC-1 cells
was slightly stimulated (Figure 3(c)). These results indicate a
close correlation between cell growth and Stat3 activation. In
HaCaT cells, Stat3 activity was low in serum-free conditions
and the addition of serum induced Stat3 activity. HSC-1 cells10 Journal of Skin Cancer
also showed a small decrease in Stat3 activity under serum-
free conditions and accordingly there was a small additional
activation following the addition of serum. In parallel to
Stat3 activity, the addition of serum to cells cultured in
serum-free conditions stimulated the proliferation of HaCaT
cells to a greater extent than HSC-1 cells. A recent study by
Quadros et al. [27] has shown that EGFR-dependent Stat3
activation is observed only in SCC cell lines but not in
HaCaT cells, because EGF did not activate Stat3 in HaCaT
cells. Since we did not add EGF but only serum and found
Stat3 activation in HaCaT cells, other ligands or growth
factors might have activated Stat3 in HaCaT cells. Regarding
the Stat3 activation in normal keratinocytes, Quadros et al.
[27] showed no activation by EGF in human keratinocytes
whereas Chan et al. [22] showed its activation by EGF in
mouse keratinocytes, indicating a species diﬀerence. Stat3
activation may be regulated in various ways according to
species and cell type.
In our analysis of HSC-1 cells, the DNA binding activity
of Stat3 was downregulated by AG1478 in a dose-dependent
manner. However, in spite of the nearly complete reduction
of EGFR expression following AG1478 treatment, Stat3
activation was still observed in HSC-1 cells. This suggests
the presence of an EGFR-independent activation of Stat3
in HSC-1 cells. It was shown that gp130/JAK and SRC-like
kinase contribute slightly to the EGFR-independent pathway
of Stat3 activation in SCC cell lines [27]. Alternatively, the
PI3K, catalytic, alpha gene is somatically mutated in several
kinds of human cancer [28]. The response of Stat3 and Akt
activation to serum stimulus between HaCaT and HSC-1
c e l l sp r o v i d e dac l u e .A k tw a ss t r o n g l ya c t i v a t e db ys e r u m
in HaCaT cells. In contrast, Akt activation was observed
in HSC-1 cells under serum-free condition, suggesting
persistent activation of PI3K/Akt signaling in cancer cells.
Maximum suppression was achieved by a combination
of AG1478 and wortmannin (Figure 4(d)), indicating that
EGFR and PI3K/Akt signaling directly or indirectly activate
Stat3 through independent pathways in HSC-1 cells.
Combined treatment of wortmannin and AG1478
showed an additive eﬀect on the induction of apoptosis as
wellasonthesuppressionofStat3activityinallSCCcelllines
(Figure 6). The induction of apoptosis in human SCC cells
also appeared to be inversely proportional to Stat3 activity
(Figures 3(b) and 6(b)). However, we have demonstrated
that Stat3 inhibition is not suﬃcient to induce apoptosis,
but Stat3 activation is required for cell proliferation and
tumorigenesis of SCC [1]. Shih et al. reported that Stat3
works as a strong antiapoptotic agent of TGF-β-induced
apoptosis in cooperation with PI3K/Akt [29]. In addition,
Corney et al. revealed that Akt regulates the sensitivity to
TGF-β through interaction with Smad3 [30]. These recent
data may support the proapoptotic eﬀect of the combination
of inhibitors used in this study.
We conclude that the proliferation and survival of SCC
cells is mostly maintained by Stat3 activation and that
Stat3 activation is mediated through EGFR and PI3K/Akt
activation in cutaneous SCC cell lines. This study could
provide clues to elucidate the carcinogenesis of cutaneous
SCCandleadtoanovel treatmentandtherapeuticstrategies.
Abbreviations
EGFR: Epidermal growth factor receptor
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